Intensifying Competition in mRNA-Targeted Small-Molecule Drug Discovery
First written in FY2023. 1 of 2 entries say "Worsened", first in FY2025. Latest entry: FY2025.
Veritas In Silico moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Worsened".
- FY2025WorsenedAnnual report
「In response to this trend, pharmaceutical companies with small-molecule drug-discovery and development capabilities have begun considering mRNA-targeted small-molecule drug discovery, and competition among biotech companies working in this field is expected to intensify further.」
The outlook for intensified competition has become more concrete, with the company stating that more than 20 major pharmaceutical companies in Japan and overseas have already partnered with biotech companies in the field. - FY2023First statedAnnual report
「Our drug-discovery platform provides a one-stop suite of technologies required for mRNA-targeted small-molecule drug discovery. In particular, it is distinguished by its ability to discover various substructures on mRNA for any gene in high demand among pharmaceutical companies and define target structures. We will continue working to strengthen the technological capabilities of our drug-discovery platform through new technology development and other measures. However, if the emergence of competing technologies diminishes the platform’s advantages or competition among drug-discovery platforms intensifies, our business, financial condition and operating results may be affected.」
The company identifies the risk that the emergence of competing technologies or intensifying competition among platforms could undermine its technological advantage.